Last reviewed · How we verify
IOBENZAMIC ACID
IOBENZAMIC ACID is a iobenzamic acid drug. It is currently in Phase 2 development.
Iobenzamic acid is a small molecule that works by binding to a specific target, but its exact mechanism of action is unknown.
Iobenzamic acid is a small molecule drug of the iobenzamic acid class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile, pharmacokinetics, and generic availability. Further research is needed to fully understand this compound. Its development history is also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOBENZAMIC ACID |
|---|---|
| Drug class | iobenzamic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and iobenzamic acid is a key that fits into one of those locks. When it binds, it can either unlock a new pathway for the cell to follow or block an existing one. However, since its target is unknown, we can't say exactly how it works or what it does.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOBENZAMIC ACID CI brief — competitive landscape report
- IOBENZAMIC ACID updates RSS · CI watch RSS
Frequently asked questions about IOBENZAMIC ACID
What is IOBENZAMIC ACID?
How does IOBENZAMIC ACID work?
What drug class is IOBENZAMIC ACID in?
What development phase is IOBENZAMIC ACID in?
Related
- Drug class: All iobenzamic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing